Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from Eli Lilly.

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

KEY TAKEAWAYSNovo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.